Published in Gene Therapy Weekly, November 18th, 1996
Preliminary gene therapy trials have emphasized the need for careful development and extensive preclinical testing of basic gene transfer technologies. Each gene therapy approach requires optimization of transduction protocols and vector design in order to reduce potential risks and increase efficiency.
German researchers Hans-Georg Eckert et al. have focused on improving retroviral vector design in order to obtain high and stable gene expression levels in early hematopoietic cells and their progeny ("High-Dose Multidrug Resistance in Primary Human Hematopoietic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.